Autolus Therapeutics PLC (AUTL) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... [Yahoo! Finance]
Autolus Therapeutics plc - American Depositary Shares (AUTL)
Last autolus therapeutics plc - american depositary shares earnings: 11/7 07:06 am
Check Earnings Report
US:NASDAQ Investor Relations:
autolus.com/investor-relations
Company Research
Source: Yahoo! Finance
Deferred Revenue: $7.6 million at the end of Q3 2025, up from $2.1 million in Q2 2025. Cost of Sales: $28.6 million for Q3 2025. Research and Development Expense: $27.9 million for Q3 2025, down from $40.3 million in Q3 2024. Selling, General and Administrative Expenses: $36.3 million for Q3 2025, up from $27.3 million in Q3 2024. Loss from Operations: $71.6 million for Q3 2025, compared to $67.9 million in Q3 2024. Net Loss: $79.1 million for Q3 2025, reduced from $82.1 million in Q3 2024. Cash Equivalents and Marketable Securities: $367.4 million as of September 30, 2025, compared to $588 million at the end of December 2024. Warning! GuruFocus has detected 4 Warning Signs with AUTL. Is AUTL fairly valued? Test your thesis with our free DCF calculator. Release Date: November 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points Autolus Therapeutics PLC ( NASDAQ:AUTL ) achieved market leade
Show less
Read more
Impact Snapshot
Event Time:
AUTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AUTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AUTL alerts
High impacting Autolus Therapeutics plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AUTL
News
- Autolus Therapeutics Appoints Ryan Richardson to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Autolus Therapeutics Appoints Ryan Richardson to Board of DirectorsGlobeNewswire
- NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (=26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹GlobeNewswire
- Autolus Therapeutics plc (NASDAQ:AUTL) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year [Yahoo! Finance]Yahoo! Finance
- Autolus Therapeutics: Trading At Cash Is Not Justified With This Pipeline [Seeking Alpha]Seeking Alpha
AUTL
Earnings
- 11/12/25 - Miss
AUTL
Sec Filings
- 12/3/25 - Form SCHEDULE
- 12/2/25 - Form 424B3
- 12/2/25 - Form 8-K
- AUTL's page on the SEC website